Shay Shemesh
Co-Founder, Executive VP, Chief Development & Operations OfficerMr. Shay Shemesh is a Co-Founder of Nuvectis Pharma, Inc. in July 27, 2020 and serves as its Executive Vice President, Chief Development and Operations Officer since 2020. From 2015 until 2020, he served as SVP, Clinical and Regulatory Affairs at Stemline Therapeutics, Inc. In this role, Mr. Shemesh held responsibilities for the strategic planning and operational execution of the Elzonris® Biologics License Application, with the FDA and Marketing Authorization Application with EMA, resulting in the approval of Elzonris™ in both regions for the treatment of blastic plasmacytoid dendritic cell neoplasm, an orphan hematologic malignancy. Prior to that, Mr. Shemesh was a clinical operations lead at Keryx Biopharmaceuticals, where he managed the late-stage clinical trials for Auryxia™ for the treatment of anemia in patients with non-dialysis CKD, which led to the approval of Auryxia in this indication in the US and the EU. Mr. Shemesh holds a BSc and MSc in Biotechnology from Bar Ilan University in Israel.
公司职务
- 公司名称Nuvectis Pharma, Inc.股票代码NVCT职务Co-Founder, Executive VP, Chief Development & Operations Officer共事同僚
- RBRon BentsurCo-Founder, Chairman, CEO & President
- EPEnrique PoradosuCo-Founder, Executive VP, Chief Scientific & Business Officer
- MCMichael CarsonVice President of Finance
- KHKenneth HobermanIndependent Director
- JFJames F. OlivieroIndependent Director
- MLMatthew Lee KaplanIndependent Director
- SNShannon N. WestinMember of Scientific Advisory Board
